Maharashtra’s Food and Drug Administration launches a statewide inspection drive targeting licensed Ayurvedic drug manufacturing establishments and issues enforcement actions for violations. The FDA inspects 434 licensed units across the state to assess compliance with the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and Schedule T, which sets Good Manufacturing Practices (GMP) requirements for Ayurvedic, Siddha and Unani medicines.

After the inspections, authorities issue show-cause notices to 135 manufacturers for non-compliance. In the most serious cases, the FDA permanently cancels the manufacturing licences of 10 firms, citing major quality and safety lapses that could affect the quality, safety, and efficacy of medicines and raise public health concerns. Reported issues include lack of qualified or approved technical personnel, non-functional quality-control departments, missing or inconsistent batch and raw-material records, inadequate testing documentation, and hygiene and equipment deficiencies.

Sources describe the actions as part of a broader effort to ensure adherence to Schedule T GMP standards. While all accounts focus on the crackdown and licence cancellations, they differ in emphasis: one report centers on the statewide scope and inspection figures, while the other highlights the specific categories of GMP and record-keeping violations cited by the regulator.